Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Targeted cancer chemotherapy stories

Nov 4, 2026

Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim

Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.

Nov 4, 2026·3 sources
00

Top claims

  • ▪Boehringer Ingelheim GmbH is Germany's largest pharmaceutical company by sales, ahead of Bayer AG
  • ▪The six preclinical biologic programs licensed by Boehringer Ingelheim GmbH from Sino Biopharmaceutical Limited include T-cell engagers, designed to activate and direct immune cells to destroy cancer cells
  • ▪Sino Biopharmaceutical Limited will conduct early development for all six preclinical biologic oncology programs covered in a cancer drug licensing deal signed on November 4, 2026 with Boehringer Ingelheim GmbH

Subtopics

Cancer & Oncology1Cancer immunotherapy1Drug development1Hong Kong1Pharmaceutical Industry1

Related timelines

Congress

110 stories

Trump administration

161 stories

US midterm elections

102 stories

Iran War

209 stories

Russia-Ukraine war

136 stories